Novacyt logo

Novacyt(LSE) NCYT

Market Cap£28.31MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2017)-34%
5 Year-84%
1 Year-2%
1 Month-7%
£0.39
-1.03%
-0.00Today
Novacyt last closing stock price
MetricPriceDate
Last closeGBX 39.902026-10-14
Novacyt stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-4.77%GBX 41.902026-10-07
1 month-7.21%GBX 43.002026-09-14
3 month+4.59%GBX 38.152026-07-16
Year to date+12.55%GBX 35.452025-12-31
1 year-2.09%GBX 40.752025-10-14
3 year-23.27%GBX 52.002023-10-13
5 year-84.21%GBX 252.702021-10-15
Since inception-34.45%GBX 0.602017-11-01

Novacyt Financials at a Glance

Market Cap

£28.31MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

£32.60M

Net Income (TTM)

-£33.47M

EPS (TTM)

-£0.32

P/E Ratio

-1.24

Dividend

£0.00

Beta (Volatility)

-0.00 (Low)

Price

£0.39

Volume

3,397

Open

£0.39

Previous Close

£0.39

Daily Range

£0.39 - £0.40

52-Week Range

£0.27 - £0.82

Estimated Earnings Date

Apr 29, 2027

NCYT News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Novacyt

Novacyt S.A. is a biotechnology company specializing in the research, production, and commercialization of diagnostic solutions for cancer and infectious diseases. With a strong international presence, Novacyt operates across various regions, including Europe, the United States, and Asia Pacific.

Products and Services
  • Real-time qPCR testing equipment and reagents for infectious diseases
  • Protein-based in-vitro diagnostic devices targeting infectious illnesses
  • PCR devices for life sciences and food testing industries
Growth Outlook
  • Recent quarterly revenue of £10.25 million indicates strong market demand
  • TTM gross profit margin of 49.8% reflects operational efficiency
  • Current ratio of 4.74 suggests robust liquidity position
Financial Highlights
  • Net income for Q4 2025 was -£16.56 million, showing ongoing challenges
  • Cash and cash equivalents stood at £19.12 million as of Q4 2025
  • Trailing twelve months (TTM) revenue of £51.18 million demonstrates significant sales
Novacyt S.A. has established itself as a key player in the medical devices industry, particularly in the diagnostics sector. The company's diverse product offerings cater to a wide range of healthcare needs, positioning it well for future growth. Despite facing challenges reflected in recent net income figures, the strong liquidity and operational efficiency metrics indicate potential for recovery and expansion. The recent quarterly revenue performance suggests that Novacyt is capitalizing on market opportunities, making it an intriguing option for investors interested in the biotechnology sector.
AI Generated • Sep 27, 2026

Industry

Biotechnology

Sector

Health Care

CEO

Lyn Dafydd Rees

Website

www.novacyt.com

Headquarters

Le Vésinet, IF 78110, FR

NCYT Financials

Key Financial Metrics (TTM)

Gross Margin

45.97%

Operating Margin

-45.81%

Net Income Margin

-106.09%

Return on Equity

-127.18%

Return on Capital

-39.00%

Return on Assets

-90.31%

Earnings Yield

-80.65%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

£28.31MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

72.59M

Volume

3.40K

Avg. Volume

90.47K

Financials (TTM)

Gross Profit

£14.54M

Operating Income

-£10.41M

EBITDA

£496.67K

Operating Cash Flow

-£11.81M

Capital Expenditure

-£307.81K

Free Cash Flow

-£12.12M

Cash & ST Invst.

£8.93M

Total Debt

£10.25M

Novacyt Performance Analysis

Novacyt annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31GBP 21,040,000-77.3%
20232023-12-31GBP 10,621,000-49.5%
20242024-12-31GBP 19,630,00084.8%
20252025-12-31GBP 20,029,0002.0%
Novacyt sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-09-30-48.7%
Q42025-12-31100.2%
Q12026-03-31-43.8%
Q22026-06-3099.5%
Novacyt annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31GBP -0.36164.6%
20232023-12-31GBP -0.4010.0%
20242024-12-31GBP -0.5947.6%
20252025-12-31GBP -0.32-45.2%
Novacyt sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-09-30-31.1%
Q42025-12-31-91.7%
Q12026-03-3182.7%
Q22026-06-30-101.5%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q2 2026YOY CHG

Revenue

£11.48M

+15.1%

Gross Profit

£5.31M

+23.5%

Gross Margin

46.25%

N/A

Market Cap

£28.31MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

£120.98K

N/A

Employees

234

N/A

Net Income

-£5.76M

-81.5%

EBITDA

-£3.86M

+14.3%

Quarterly Fundamentals

Name
Q2 2026YOY CHG

Total Cash

£8.93M

-62.6%

Total Debt

£10.25M

-6.4%

Accounts Receivable

£5.04M

+9.0%

Inventory

£4.52M

+75.5%

Long Term Debt

£9.22M

-7.7%

Short Term Debt

£1.03M

-42.3%

Return on Assets

-90.31%

N/A

Return on Invested Capital

-46.94%

N/A

Free Cash Flow

-£4.52M

+16.7%

Operating Cash Flow

-£4.40M

+16.1%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
RENX.LRenalytix Plc
£0.05+1.87%
SAR.LSareum Holdings plc
£0.28+0.01%
RUA.LRUA Life Sciences plc
£0.29-3.33%
IHC.LInspiration Healthcare Group plc
£0.19+0.00%

Trending Stocks

Symbol / CompanyPricePrice Chg
BACBank of America
$51.05-5.40%
CRWVCoreWeave
$65.46-15.87%
SOXSDirexion Shares ETF Trust - Direxion Daily Semiconductor Bear 3x ETF
$42.27+12.96%
SOXLDirexion Shares ETF Trust - Direxion Daily Semiconductor Bull 3x ETF
$111.28-12.77%

Questions About NCYT

What is the current price of Novacyt?

Novacyt is trading at £0.39 per share.

What is the 52-week range for Novacyt?

Over the past 52 weeks, Novacyt has traded between £0.27 and £0.82.

How much debt does Novacyt have?

As of the most recent reporting period, Novacyt reported total debt of £10.45M.

How much cash does Novacyt have on hand?

Novacyt reported £19.15M in cash and cash equivalents in its most recent financial results.

What is Novacyt’s dividend yield?

Novacyt does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services